Infliximab and Adalimumab-induced Thrombocytopenia in a Woman with Colonic Crohn's Disease

Overview

Journal Gut

Specialty Gastroenterology

Date 2007 Mar 9

PMID 17344276

Citations 5

Authors

Antonio Salar

Xavier Bessa

Eduard Muniz

David Monfort

Carlos Besses

Montserrat Andreu

Affiliations

Soon will be listed here.

Citing Articles

Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature.

Grillo T, Silveira C, Quaglio A, de Medeiros Dutra R, Baima J, Bazan S World J Cardiol. 2023; 15(5):217-228.

PMID: 37274378 PMC: 10237008. DOI: 10.4330/wjc.v15.i5.217.

Case Report: Severe thrombocytopenia induced by adalimumab in rheumatoid arthritis: A case report and literature review.

Liao T, Li M, Yuan T, Hong Q, Zeng Y, Yu D Front Pharmacol. 2022; 13:1041884.

PMID: 36386149 PMC: 9640920. DOI: 10.3389/fphar.2022.1041884.

A case of "smoldering" immune-mediated thrombotic thrombocytopenic purpura manifesting as recurrent cardioembolic stroke.

Pepin M, Saca E, Kwon S, May J Clin Case Rep. 2021; 9(10):e04850.

PMID: 34667601 PMC: 8507438. DOI: 10.1002/ccr3.4850.

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study.

Veisman I, Barzilay O, Bruckmayer L, Haj-Natour O, Kopylov U, Eliakim R J Clin Med. 2021; 10(18).

PMID: 34575376 PMC: 8471987. DOI: 10.3390/jcm10184265.

Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System.

Gogoleva V, Atretkhany K, Dygay A, Yurakova T, Drutskaya M, Nedospasov S Front Immunol. 2021; 12:661900.

PMID: 34054827 PMC: 8155636. DOI: 10.3389/fimmu.2021.661900.

References

Marotte H, Charrin J, Miossec P . Infliximab-induced aseptic meningitis. Lancet. 2001; 358(9295):1784. DOI: 10.1016/S0140-6736(01)06810-6. View

Vidal F, Fontova R, Richart C . Severe neutropenia and thrombocytopenia associated with infliximab. Ann Intern Med. 2003; 139(3):W-W63. DOI: 10.7326/0003-4819-139-3-200308050-00021-w4. View

Travis S, Stange E, Lemann M, Oresland T, Chowers Y, Forbes A . European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 Suppl 1:i16-35. PMC: 1859997. DOI: 10.1136/gut.2005.081950b. View

Hamaguchi M, Kawahito Y, Ishino H, Yoshida M, Yoshikawa T . A case report of tumor necrosis factor-alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin Rheumatol. 2006; 26(6):988-90. DOI: 10.1007/s10067-006-0229-y. View

Van Dullemen H, van Deventer S, Hommes D, Bijl H, Jansen J, Tytgat G . Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109(1):129-35. DOI: 10.1016/0016-5085(95)90277-5. View